Results 11 to 20 of about 74,852 (258)

Advances in the use of PARP inhibitor therapy for breast cancer [PDF]

Drugs in Context, 2018
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj   +2 more sources

A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer

Сибирский онкологический журнал, 2022
Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert, I. A. Kolomiets, Y. A. Fesik, A. A. Ivanova, N. V. Yunusova, О. N. Churuksaeva   +5 more
doaj   +1 more source

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

Frontiers in Pharmacology, 2022
Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht, V. Udaya Kumar, Ruchi Pandey, Ravichandiran Velayutham, Nitesh Kumar   +4 more
doaj   +1 more source

Drug-Induced Interstitial Lung Disease From PARP Inhibitors (Olaparib and Niraparib) for Ovarian Cancer

Annals of Internal Medicine: Clinical Cases, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto, Takanori Enomoto, Mamoru Okuno, Naoko Chayahara, Hiroki Morita, Kyosuke Nakata   +5 more
doaj   +1 more source

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

The Journal of Clinical Investigation, 2022
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations ...
Zhen Lu, Weiqun Mao, Hailing Yang, Janice M. Santiago-O’Farrill, Philip J. Rask, Jayanta Mondal, Hu Chen, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Yuanxin Xi, Kenta Masuda, Eli M. Carrami, Meng Chen, Yitao Tang, Lan Pang, David S. Lakomy, George A. Calin, Han Liang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr.   +21 more
doaj   +1 more source

PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities

Frontiers in Pharmacology, 2023
Background: Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been extensively studied due to its regulatory role in numerous biologically crucial pathways.
Wen-Hao Li, Fei Wang, Gui-Yuan Song, Qing-Hua Yu, Rui-Peng Du, Ping Xu, Ping Xu   +6 more
doaj   +1 more source

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer

Frontiers in Oncology, 2021
Poly (ADP-ribose) polymerase (PARP) inhibitors constitute an important treatment option for ovarian cancer nowadays. The magnitude of benefit from PARP inhibitors is influenced by the homologous recombination status, with greater benefit observed in ...
Renata Colombo Bonadio, Renata Colombo Bonadio, Maria del Pilar Estevez-Diz, Maria del Pilar Estevez-Diz   +3 more
doaj   +1 more source

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

Journal of Ovarian Research, 2023
As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang, Yu Wang   +4 more
doaj   +1 more source

Hypersensitivity of BRCA1 heterozygote lymphoblastoid cells to gamma radiation and PARP inhibitors [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright @ 2013 Bourton EC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use ...
Bourton, EC, Plowman, PN, Parris, C, Parris, CN, Foster, HA, Harvey, AJ   +5 more
core   +1 more source

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo

EBioMedicine, 2016
The clinical potential of PARP-1 inhibitors has been recognized >10 years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology.
Colin Thomas, Yingbiao Ji, Niraj Lodhi, Elena Kotova, Aaron Dan Pinnola, Konstantin Golovine, Peter Makhov, Kate Pechenkina, Vladimir Kolenko, Alexei V. Tulin   +9 more
doaj   +1 more source